• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于使用泻药和结肠黑变病作为结直肠肿瘤危险因素的回顾性研究。

Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma.

作者信息

Nusko G, Schneider B, Müller G, Kusche J, Hahn E G

机构信息

Department of Medicine I, University of Erlangen-Nürnberg, FRG.

出版信息

Pharmacology. 1993 Oct;47 Suppl 1:234-41. doi: 10.1159/000139863.

DOI:10.1159/000139863
PMID:8234435
Abstract

In a retrospective study a cohort of 2,277 patients was defined by colonoscopy. Among other factors it was tested whether in these patients laxative use or the endoscopically diagnosed presence of melanosis coli were risk factors related to colorectal neoplasma. In comparison to patients taking no laxatives there was no significant increase in colorectal cancer rate either in laxative users or in patients with melanosis coli. However, there was a statistically significant association between the occurrence of colorectal adenomas and laxative use (relative risk of all patients exposed to laxatives = 1.72; of patients exposed to laxatives without melanosis coli = 1.47). The relative risk of adenoma development in patients with melanosis coli was 2.19. Taking into account that polyps can be diagnosed in the dark mucosa of melanosis coli patients more easily, even this relative risk of 2.19 seems to be related to a generally enhanced risk of laxative intake rather than to a special group of (anthranoid containing) laxatives.

摘要

在一项回顾性研究中,通过结肠镜检查确定了2277名患者组成的队列。除其他因素外,还检测了这些患者使用泻药或内镜诊断出的结肠黑变病是否为与结直肠肿瘤相关的危险因素。与未使用泻药的患者相比,泻药使用者或结肠黑变病患者的结直肠癌发生率均未显著增加。然而,结直肠腺瘤的发生与使用泻药之间存在统计学上的显著关联(所有暴露于泻药的患者的相对风险 = 1.72;暴露于泻药但无结肠黑变病的患者的相对风险 = 1.47)。结肠黑变病患者发生腺瘤的相对风险为2.19。考虑到在结肠黑变病患者的深色黏膜中更容易诊断出息肉,即使这种2.19的相对风险似乎也与泻药摄入普遍增加的风险有关,而不是与特定的(含蒽类)泻药有关。

相似文献

1
Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma.关于使用泻药和结肠黑变病作为结直肠肿瘤危险因素的回顾性研究。
Pharmacology. 1993 Oct;47 Suppl 1:234-41. doi: 10.1159/000139863.
2
Melanosis coli--a harmless pigmentation or a precancerous condition?结肠黑变病——一种无害的色素沉着还是癌前病变?
Z Gastroenterol. 1997 May;35(5):313-8.
3
Anthranoid laxative abuse--a risk for colorectal cancer?蒽醌类泻药滥用——会引发结直肠癌吗?
Gut. 1993 Aug;34(8):1099-101. doi: 10.1136/gut.34.8.1099.
4
Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study.蒽醌类泻药的使用并非结直肠肿瘤的风险因素:一项前瞻性病例对照研究的结果
Gut. 2000 May;46(5):651-5. doi: 10.1136/gut.46.5.651.
5
Constipation, anthranoid laxatives, melanosis coli, and colon cancer: a risk assessment using aberrant crypt foci.便秘、蒽醌类泻药、结肠黑变病与结肠癌:一项使用异常隐窝病灶的风险评估
Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):753-7.
6
Soft-tissue images. Melanosis coli.软组织图像。结肠黑变病。
Can J Surg. 2000 Dec;43(6):407-8.
7
Retrospective study on melanosis coli as risk factor of colorectal neoplasm: a 3-year colonoscopic finding in Zhuhai Hospital, China.回顾性研究结肠黑变病作为结直肠肿瘤的危险因素:中国珠海医院的 3 年结肠镜检查结果。
Int J Colorectal Dis. 2020 Feb;35(2):213-222. doi: 10.1007/s00384-019-03435-7. Epub 2019 Dec 10.
8
Anthranoid self-medication causing rapid development of melanosis coli.蒽醌类药物自我药疗导致结肠黑变病快速发展。
Neth J Med. 2003 Jan;61(1):22-4.
9
Melanosis coli: Harmless pigmentation? A case-control retrospective study of 657 cases.结肠黑变病:无害的色素沉着?一项对657例病例的病例对照回顾性研究。
PLoS One. 2017 Oct 31;12(10):e0186668. doi: 10.1371/journal.pone.0186668. eCollection 2017.
10
Melanosis coli in inflammatory bowel disease.炎症性肠病中的结肠黑变病。
J Clin Gastroenterol. 1998 Apr;26(3):167-70. doi: 10.1097/00004836-199804000-00003.

引用本文的文献

1
Development of an LC-DAD-MS-Based Method for the Analysis of Hydroxyanthracene Derivatives in Food Supplements and Plant Materials.建立一种基于 LC-DAD-MS 的方法,用于分析食品补充剂和植物材料中的羟基蒽衍生物。
Molecules. 2022 Mar 16;27(6):1932. doi: 10.3390/molecules27061932.
2
Anthraquinone laxatives use and colorectal cancer: A systematic review and meta-analysis of observational studies.蒽醌类泻药的使用与结直肠癌:观察性研究的系统评价和荟萃分析。
Phytother Res. 2022 Mar;36(3):1093-1102. doi: 10.1002/ptr.7373. Epub 2022 Jan 17.
3
Pseudomelanosis coli, its relation to laxative use and association with colorectal neoplasms: A comprehensive review.
结肠假黑色素沉着症、其与泻药使用的关系以及与结直肠肿瘤的关联:一项全面综述。
JGH Open. 2021 May 4;5(6):643-646. doi: 10.1002/jgh3.12546. eCollection 2021 Jun.
4
Safety of hydroxyanthracene derivatives for use in food.用于食品中的羟基蒽衍生物的安全性。
EFSA J. 2018 Jan 23;16(1):e05090. doi: 10.2903/j.efsa.2018.5090. eCollection 2018 Jan.
5
Retrospective study on melanosis coli as risk factor of colorectal neoplasm: a 3-year colonoscopic finding in Zhuhai Hospital, China.回顾性研究结肠黑变病作为结直肠肿瘤的危险因素:中国珠海医院的 3 年结肠镜检查结果。
Int J Colorectal Dis. 2020 Feb;35(2):213-222. doi: 10.1007/s00384-019-03435-7. Epub 2019 Dec 10.
6
Melanosis Coli: A Helpful Contrast Effect or a Harmful Pigmentation?结肠黑变病:有益的对比效果还是有害的色素沉着?
Clin Med Insights Gastroenterol. 2018 Dec 4;11:1179552218817321. doi: 10.1177/1179552218817321. eCollection 2018.
7
Identification of candidate biomarkers associated with apoptosis in melanosis coli: GNG5, LPAR3, MAPK8, and PSMC6.鉴定与大肠黑变病细胞凋亡相关的候选生物标志物:GNG5、LPAR3、MAPK8 和 PSMC6。
Biosci Rep. 2019 Jan 18;39(1). doi: 10.1042/BSR20181369. Print 2019 Jan 31.
8
Gender, age, and concomitant diseases of melanosis coli in China: a multicenter study of 6,090 cases.中国结肠黑变病的性别、年龄及伴发疾病:一项纳入6090例病例的多中心研究
PeerJ. 2018 Mar 8;6:e4483. doi: 10.7717/peerj.4483. eCollection 2018.
9
Melanosis coli in patients with colon cancer.结肠癌患者的结肠黑变病。
Prz Gastroenterol. 2017;12(1):22-27. doi: 10.5114/pg.2016.64844. Epub 2016 Dec 29.
10
A prospective study of the effect of bowel movement frequency, constipation, and laxative use on colorectal cancer risk.一项关于排便频率、便秘及泻药使用对结直肠癌风险影响的前瞻性研究。
Am J Gastroenterol. 2014 Oct;109(10):1640-9. doi: 10.1038/ajg.2014.233. Epub 2014 Sep 16.